ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a research note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set an "overweight" rating and a $85.00 price target on the specialty pharmaceutical company's stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 38.44% from the company's current price.

Several other research firms have also commented on ANIP. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Guggenheim upped their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $79.75.

Remove Ads

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $61.40 on Wednesday. The business has a 50-day moving average of $57.86 and a 200 day moving average of $58.07. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -111.64 and a beta of 0.62. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,300 shares of company stock worth $584,869. 12.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Thrivent Financial for Lutherans raised its stake in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after buying an additional 299 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after acquiring an additional 310 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after acquiring an additional 364 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares during the period. Finally, Natixis Advisors LLC grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after purchasing an additional 417 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.